Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
PetVivo Holdings, Inc. (NASDAQ: PETV) is a veterinary medical device and animal health company focused on the development, commercialization, and licensing of innovative therapies for companion animals, with an initial emphasis on osteoarthritis and joint-related conditions. The company operates within the animal health, veterinary medical devices, and biomaterials industries, targeting chronic conditions that impact mobility and quality of life in animals.
The company’s primary revenue drivers are proprietary biomaterial-based therapies derived from its OsteoCushion® Technology, which is designed to function as a synthetic cartilage and shock absorber within animal joints. PetVivo primarily serves veterinary professionals, animal hospitals, and equine and companion animal owners, positioning itself as a niche innovator in regenerative and therapeutic veterinary solutions. The company traces its origins to earlier biomaterials research and was rebranded as PetVivo Holdings, Inc. as it narrowed its strategic focus to animal health and commercialization of veterinary-specific products.
Business Operations
PetVivo conducts its operations primarily through its wholly owned subsidiary PetVivo Animal Health, Inc., which is responsible for product development, regulatory strategy, manufacturing coordination, and commercialization. The company’s core business centers on the development and sale of veterinary medical devices and biologic-like therapies, with revenues generated through direct product sales, licensing arrangements, and strategic commercialization partnerships.
Operations are primarily U.S.-based, with commercialization supported through veterinary distribution channels and strategic partners. PetVivo controls proprietary biomaterial formulations, intellectual property related to injectable joint therapies, and manufacturing processes outsourced to qualified third parties. The company has entered into commercialization and development collaborations with established animal health companies to expand market access and leverage existing veterinary sales infrastructures. Data regarding additional joint ventures or subsidiaries beyond its primary operating entity is inconclusive based on available public sources.
Strategic Position & Investments
PetVivo’s strategic direction centers on expanding the clinical applications and market penetration of its OsteoCushion® Technology across multiple animal species. Growth initiatives include product line expansion beyond equine applications into the companion animal market, increased veterinary adoption, and broader geographic commercialization through partnerships. A notable strategic initiative includes the development and commercialization of SPRYNG®, an injectable osteoarthritis therapy for dogs developed in collaboration with Elanco Animal Health.
The company has historically emphasized internal research and development over large-scale acquisitions, focusing capital allocation on regulatory approvals, clinical validation, and intellectual property protection. PetVivo does not currently report a diversified investment portfolio or multiple operating subsidiaries, and information regarding material equity investments or acquisitions beyond its core operations is limited in public disclosures.
Geographic Footprint
PetVivo is headquartered in the United States, with its principal executive offices located in Minnesota. The company’s primary commercial focus remains the North American veterinary market, particularly the United States, where regulatory approvals and veterinary distribution networks are most developed.
Internationally, PetVivo’s presence is largely indirect, achieved through licensing discussions, distributor relationships, and strategic collaborations rather than wholly owned foreign operations. While management has indicated interest in expanding into additional global markets, particularly in regions with advanced veterinary care infrastructure, the extent of current international operational influence remains limited based on publicly available information.
Leadership & Governance
PetVivo is led by an executive team with experience in medical devices, biomaterials, and animal health commercialization. The company’s leadership emphasizes disciplined capital deployment, strategic partnerships, and long-term value creation through proprietary technology development and regulatory execution.
Key executives include:
- John Lai – Chief Executive Officer
- Larry Berman – Chief Financial Officer
- Ryan Miller – President
- Dr. Robert L. Harman – Vice President of Research & Development
The board and executive leadership collectively guide corporate governance, strategic planning, and risk oversight, with a stated focus on advancing clinically differentiated veterinary solutions and expanding shareholder value through commercialization milestones.